In the last trading session, 12.65 million CytomX Therapeutics Inc (NASDAQ:CTMX) shares changed hands as the company’s beta touched 1.03. With the company’s per share price at $1.23 changed hands at $0.14 or 12.84% during last session, the market valuation stood at $96.26M. CTMX’s last price was a discount, traded about -375.61% off its 52-week high of $5.85. The share price had its 52-week low at $0.83, which suggests the last value was 32.52% up since then. When we look at CytomX Therapeutics Inc’s average trading volume, we note the 10-day average is 0.87 million shares, with the 3-month average coming to 845.16K.
Analysts gave the CytomX Therapeutics Inc (CTMX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended CTMX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. CytomX Therapeutics Inc’s EPS for the current quarter is expected to be -0.13.
CytomX Therapeutics Inc (NASDAQ:CTMX) trade information
Instantly CTMX was in green as seen at the end of in last trading. With action 28.08%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -20.65%, with the 5-day performance at 28.08% in the green. However, in the 30-day time frame, CytomX Therapeutics Inc (NASDAQ:CTMX) is 17.14% up. Looking at the short shares, we see there were 4.44 million shares sold at short interest cover period of 4.41 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5.84, meaning bulls need an upside of 78.94% from its current market value. According to analyst projections, CTMX’s forecast low is 3.25 with 8 as the target high. To hit the forecast high, the stock’s price needs a -550.41% plunge from its current level, while the stock would need to soar -164.23% for it to hit the projected low.
CytomX Therapeutics Inc (CTMX) estimates and forecasts
Data shows that the CytomX Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -26.79% over the past 6 months, a -400.00% in annual growth rate that is considerably lower than the industry average of 17.60%. Year-over-year growth is forecast to reach 14.33% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 13.53M. 3 analysts are of the opinion that CytomX Therapeutics Inc’s revenue for the current quarter will be 18.5M. The company’s revenue for the corresponding quarters a year ago was 26.61M and 41.46M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -49.14%. The estimates for the next quarter sales put growth at -55.38%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 67.21%. The 2024 estimates are for CytomX Therapeutics Inc earnings to decrease by -328.04%, but the outlook for the next 5-year period is at -0.90% per year.
CTMX Dividends
CytomX Therapeutics Inc is expected to release its next quarterly earnings report in January.
CytomX Therapeutics Inc (NASDAQ:CTMX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.00% of CytomX Therapeutics Inc shares while 65.62% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 66.29%. There are 65.62% institutions holding the CytomX Therapeutics Inc stock share, with TANG CAPITAL MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 9.4989% of the shares, roughly 7.79 million CTMX shares worth $9.51 million.
JANUS HENDERSON GROUP PLC holds the second largest percentage of outstanding shares, with 7.6826% or 6.3 million shares worth $7.72 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jun 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . With 2.19 shares estimated at $2.69 million under it, the former controlled 2.79% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 1.25% of the shares, roughly 981.49 shares worth around $1.21 million.
